Clinical Trial Update: Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection) [Phase 1]

View source ↗

Summary

Phase 1 study of HT-102 administered subcutaneously in healthy participants and chronic hepatitis B patients to evaluate safety, tolerability, pharmacokinetics,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• HT-102

Snippet

Sponsor: Suzhou HepaThera Biotech Co., Ltd. | Conditions: Chronic Hepatitis B | Phase 1 | Status: COMPLETED